Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C)....
Dyslipidemia is an independent risk factor of cardiovascular diseases (CVDs), which lead to the high mortality, disability, and medical expenses in the worldwide. Based on the previous researches, the improvement of dyslipidemia could efficiently prevent the occurrence and progress of cardiovascular dise...
Cardiovascular disease (CVD) remains the predominant cause of mortality and disability worldwide. Against this backdrop, finding effective drugs for the pharmacological treatment of CVD has become one of the most urgent and challenging issues in medical
Includes hepatotoxicity of sustained-release niacin formulations; Diagnosing insulin resistance; Characteristics of diabetic patient who can take niacin.doi:10.1016/S0002-9149(98)00956-4John R GuytonThe American Journal of CardiologyGuyton, Advances in Dyslipidemia: Discussion Session II, Am. J. Cardiol...
L-T4 replacement therapy reduces the prevalence of MASLD, especially in patients with severe SCH or mild SCH with dyslipidemia. Recent studies showed that thyroid hormone analogues and thyroid hormone β receptor agonists obtained positive results in the treatment of MASLD in animal models and ...
The adoption of interventions of different intensities based on the risk of ASCVD is the core strategy for the prevention and treatment of dyslipidemia, and the overall ASCVD risk assessment is the basis for treatment decisions related to dyslipidemia [173]. Among the commonly used lipid markers, ...
including exacerbation of heart failure, neuro-demyelinating lesions and dyslipidemia [219,220]. Therefore, it is crucial for clinicians to use TNF drugs judiciously and regularly monitor their patients. The mechanism by which TNF-α functions likely involves the activation of macrophages, interactions ...
Lipid metabolism in cancer is characterized by dysregulated lipid regulation and utilization, critical for promoting tumor growth, survival, and resistance to therapy. Pancreatic cancer (PC) is a highly aggressive malignancy of the gastrointestinal tract
result in unexpectedly decreased membrane diffusive permeability, increased serum albumin/protein loss, inflammatory cytokine release and oxidative stress and promote thrombus formation in the extracorporeal blood circuit, occlusion of hollow fibers and early termination of dialysis treatment in the worst ...
Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004–1009. doi:10.1212/01.wnl.0000285080.70324...